Revvity (RVTY) FX & Other Adjustments — Quarterly & Annual

Screener

FX & Other Adjustments at other companies

Bio-Rad LaboratoriesBIO

——

Segments

By segment

Life Sciences-$24.95M-174%

Diagnostics$3.63M—

Other financials

Income statement

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

Market cap$12.83B+28.7%

Enterprise value$15.91B+28.6%

P/E53.5×+18.6×

P/S4.4×+0.9×

Profitability

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 4:07 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000031791-26-000019

Line item	Life Sciences	Diagnostics	Consolidated
Balance at December 28, 2025	$4,744,962	$1,868,531	$6,613,493
Foreign currency translation	(24,952)	(9,826)	(34,778)
Acquisitions	32,035	—	32,035
Balance at April 5, 2026	$4,752,045	$1,858,705	$6,610,750

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's FX & other adjustments?: Revvity (RVTY) reported FX & other adjustments of -$34.78M in Q1 2026.
How has Revvity's FX & other adjustments changed year-over-year?: Revvity's FX & other adjustments decreased by 172.7% year-over-year, from $47.87M to -$34.78M.

Ask your AI about Revvity's fx & other adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk